prof. Guy Laureys

Journal Article
A2
open access

Concurrent ocular and cerebral toxoplasmosis in a liver transplant patient treated with anti-CD40 monoclonal antibody

Roos Van Den Noortgate (UGent) , Maja Kiselinova (UGent) , CELINE SYS (UGent) , Geraldine Accou (UGent) , Guy Laureys (UGent) , Hans Van Vlierberghe (UGent) , Frederik Berrevoet (UGent) and Elke O. Kreps (UGent)

(2023) CASE REPORTS IN INFECTIOUS DISEASES. 2023.

Add to list

Journal Article
A1
open access

Disability accrual in primary and secondary progressive multiple sclerosis

Sam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, Charles B Malpas, Ibrahima Diouf, Nahid Moradi, Sifat Sharmin, Guillermo Izquierdo, Sara Eichau, Francesco Patti, et al.

(2023) JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY.

Add to list

Journal Article
A1
open access

Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis

Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S. Freedman, Harold Atkins, Joachim Burman, Jennifer Massey, Ian Sutton, Barbara Withers, Richard Macdonell, et al.

(2023) JAMA NEUROLOGY. 80(7). p.702-713

Add to list

Journal Article
A1
open access

Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

Chao Zhu, Tomas Kalincik, Dana Horakova, Zhen Zhou, Katherine Buzzard, Olga Skibina, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Jens Kuhle, et al.

(2023) JAMA NEUROLOGY. 80(7). p.739-748

Add to list

Journal Article
A2
open access

A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis : results from the MSBase registry

Tim Spelman, Serkan Ozakbas, Raed Alroughani, Murat Terzi, Suzanne Hodgkinson, Guy Laureys (UGent) , Tomas Kalincik, Anneke Van Der Walt, Bassem Yamout, Jeannette Lechner-Scott, et al.

(2023) NEURODEGENERATIVE DISEASE MANAGEMENT. 13(4). p.215-221

Add to list

Journal Article
A1
open access

Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis

Izanne Roos, Stella Hughes, Gavin McDonnell, Charles B. Malpas, Sifat Sharmin, Cavit Boz, Raed Alroughani, Serkan Ozakbas, Katherine Buzzard, Olga Skibina, et al.

(2023) JAMA NEUROLOGY.

Add to list

Journal Article
A1
open access

Influence of physicians’ risk perception on switching treatments between high- efficacy and non–high-efficacy disease‑modifying therapies in multiple sclerosis

Gustavo Seifer, Tarunya Arun, Carlos Capela, Guy Laureys (UGent) , Eddie Jones, Patricia Dominguez-Castro, Rainel Sanchez-de la Rosa, Simone Hiltl and Pietro Iaffaldano

(2023) MULTIPLE SCLEROSIS AND RELATED DISORDERS. 76.

Add to list

Journal Article
A1
open access

Exome sequencing and multigene panel testing in 1,411 patients with adult-onset neurologic disorders

Nika Schuermans (UGent) , Hannah Verdin (UGent) , Jody Ghijsels (UGent) , Madeleine Hellemans (UGent) , Elke Debackere (UGent) , Elke Bogaert (UGent) , Sofie Symoens (UGent) , Leslie Naesens (UGent) , Elien Lecomte, David Crosiers, et al.

(2023) NEUROLOGY-GENETICS. 9(3).

Add to list

Journal Article
A1
open access

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

C Daruwalla, V Shaygannejad, S Ozakbas, EK Havrdova, D Horakova, R Alroughani, C Boz, F Patti, M Onofrj, A Lugaresi, et al.

(2023) MULTIPLE SCLEROSIS JOURNAL. 29(7). p.875-883

Add to list

Journal Article
A1
open access

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis : results from MSBase registry

T Spelman, S Ozakbas, R Alroughani, M Terzi, S Hodgkinson, Guy Laureys (UGent) , T Kalincik, A Van Der Walt, B Yamout, J Lechner-Scott, et al.

(2023) MULTIPLE SCLEROSIS JOURNAL. 29(2). p.221-235

Academic Bibliography

prof. Guy Laureys

Concurrent ocular and cerebral toxoplasmosis in a liver transplant patient treated with anti-CD40 monoclonal antibody

Disability accrual in primary and secondary progressive multiple sclerosis

Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis

Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis : results from the MSBase registry

Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis

Influence of physicians’ risk perception on switching treatments between high- efficacy and non–high-efficacy disease‑modifying therapies in multiple sclerosis

Exome sequencing and multigene panel testing in 1,411 patients with adult-onset neurologic disorders

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis : results from MSBase registry

Contents

Support

Contact